Sun, Jan 25, 2015, 9:47 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • blackoutbuzz blackoutbuzz Mar 29, 2012 12:31 PM Flag

    New Replagal data

    I assume this is to demonstrate that there is no long term concern switching from Fabrazyme to Replagal.

    NYON, Switzerland, March 29, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented data that show favorable treatment effect and tolerability of REPLAGAL® (agalsidase alfa) in Fabry patients who switched from Fabrazyme® (agalsidase beta) or were naive to enzyme replacement therapy (ERT) after one year of treatment with REPLAGAL at the America College of Medical Genetics (ACMG) annual meeting in Charlotte, NC.

216.03+2.27(+1.06%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.